Full Description
Cancer Drug Design and Discovery, Second Edition is an important reference on the underlying principles for the design and subsequent development of new anticancer small molecule agents. New chapters have been added to this edition on areas of particular interest and therapeutic promise, including cancer genomics and personalized medicine, DNA-targeted agents and more. This book includes several sections on the basic and applied science of cancer drug discovery and features those drugs that are now approved for human use and are in the marketplace, as well as those that are still under development. By highlighting some of the general principles involved in taking molecules through basic science to clinical development, this book offers a complete and authoritative reference on the design and discovery of anticancer drugs for translational scientists and clinicians involved in cancer research.
Contents
Introduction - Stephen Neidle
Foreword - Hilary Calvert
Part I. Basic Principles and methodology
Modern cancer drug discovery: integrating targets, technologies and treatments — Paul Workman and
Ian Collins
Pharmacogenomics and personalised medicines in cancer treatment — Wei-Peng Yong, Ross Soo and
Federico Innocenti
Structural biology and anticancer drug design — Puja Pathuri, David Norton, Henriette Willems,
Dominic Tisi and Harren Jhoti
Part II. Drugs in the laboratory and clinic
Temozolomide: from cytotoxic to molecularly-targeted agent — Malcolm Stevens
Temozolomide: patents and the perils of invention — Malcolm Stevens
A new generation of cell-targeted drugs for cancer treatment — Paola B. Arimondo, Nicolas Guilbaud
and Christian Bailly
Inhibition of DNA repair as a therapeutic target — Stephany Veuger and Nicola J Curtin
Inhibitors of tumour angiogenesis — Adrian L. Harris and Daniele G Generali
The Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer — Qingzhong Hu and Rolf
W. Hartmann
Apoptosis in Cancer: Mechanisms, Deregulation and Therapeutic Targeting — Zahid H Siddik
Targeting the MDM2-p53 protein-protein interaction: design, discovery and development of novel
anticancer agents — Ian R Hardcastle
Targeting altered metabolism - emerging cancer therapeutic strategy — Minsuh Seo, Robert Blake
Crochet and Yong-Hwan Lee
Inhibitors of the Phosphatidylinositol 3-kinase (PI3K) Pathway — William A Denny and Gordon W.
Rewcastle
Antibody-drug conjugates delivering DNA cytotoxics — John A Hartley
Inhibition of telomerase: promise, progress and potential pitfalls — Christopher G. Tomlinson, Scott B.
Cohen and Tracy M. Bryan
Targeting B-RAF: the discovery and development of B-RAF inhibitors — Phillip A Harris
Part III. The reality of cancer drugs in the clinic
Failure Modes in Anticancer Drug Discovery and Development — Richard A. Walgren and
Christopher. A. Slapak
Anticancer drug registration and regulation: current challenges and possible solutions — David
Taylor, Erling Donnelly and Silvia Chioato
